PDT Partners’s Keros Therapeutics KROS Stock Holding History

PDT Partners’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$361K	Sell	32,744 -79,439	-71%	-$1.23M	0.02%	448
2025 Q4	$2.28M	Sell	112,183 -220,632	-66%	-$3.87M	0.15%	228
2025 Q3	$5.27M	Hold	332,815	–	–	0.33%	94
2025 Q2	$4.44M	Buy	332,815 +56,755	+21%	+$766K	0.25%	136
2025 Q1	$2.81M	Buy	+276,060	New	+$3.21M	0.2%	178
2023 Q2	–	Sell	-22,657	Closed	-$967K	–	619
2023 Q1	$967K	Buy	22,657 +56	+0.2%	+$2.83K	0.13%	270
2022 Q4	$1.09M	Sell	22,601 -62	-0.3%	-$2.9K	0.18%	201
2022 Q3	$853K	Sell	22,663 -24,883	-52%	-$862K	0.13%	267
2022 Q2	$1.31M	Buy	47,546 +30,391	+177%	+$1.33M	0.12%	299
2022 Q1	$933K	Buy	+17,155	New	+$881K	0.08%	401
2021 Q2	–	Sell	-3,876	Closed	-$239K	–	893
2021 Q1	$239K	Buy	+3,876	New	+$246K	0.02%	664

Other funds holding KROS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

PDT Partners's KROS Position: Q1 2026 in Review

PDT Partners reduced its Keros Therapeutics (KROS) stake by 71% in Q1 2026, selling an estimated $1.23M and leaving 32,744 shares worth $361K. The position accounts for 0.02% of the portfolio, ranked #448.

PDT Partners first reported a position in KROS in Q1 2021 and has held it in 11 quarters since. The position peaked at $5.27M in Q3 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

PDT Partners held 32,744 shares of Keros Therapeutics worth $361K as of Q1 2026.
PDT Partners sold 79,439 Keros Therapeutics shares in Q1 2026, an estimated $1.23M.
Keros Therapeutics made up 0.02% of PDT Partners's portfolio in Q1 2026, its #448 holding.
PDT Partners first reported a position in Keros Therapeutics in Q1 2021 and has held it in 11 quarters since.
PDT Partners's Keros Therapeutics position peaked at $5.27M in Q3 2025.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.